Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo.
OBJECTIVE
The aim of this study was to investigate the regional differences in the in vivo vasodilator responses to vasopressin, which is thought to stimulate the release of nitric oxide from the endothelium, in canine cerebral arteries by angiography.


METHODS
Angiograms were performed through a catheter inserted directly into the right vertebral artery and were taken periodically after the infusion of vasopressin. The diameters of various segments of the major arteries were measured using a computerized image analysis system.


RESULTS
The bolus administration of vasopressin (10 pmol to 1 nmol) into the vertebral artery produced a long-lasting, dose-dependent vasodilation in the major cerebral arteries centering around the circle of Willis. One nanomole of vasopressin appeared to be the optimal dose for producing maximal vasodilation. The internal diameters of the basilar, posterior communicating, and internal carotid arteries experienced the most dilation (approximately 150% that of control) 2 minutes after the infusion of 1 nmol of vasopressin, followed by those of the middle cerebral, the intracranial portion of the vertebral, and the anterior spinal arteries (approximately 130% that of control). The extracranial portion of the vertebral artery (109.8 +/- 4.8% that of control, n = 4) was less sensitive to 1 nmol of vasopressin. Pretreatment with an intracisternal injection of 10 mumol of NG-monomethyl L-arginine suppressed the vasodilator effect of vasopressin and substance P, whereas it did not affect the response to vasoactive intestinal peptide.


CONCLUSIONS
These results suggest that the arteries composing the circle of Willis at the base of the brain are more sensitive to nitric oxide release induced by vasopressin compared with other intracranial and extracranial arteries.
Suzuki
Y
Y
Department of Neurosurgery, Nagoya University School of Medicine, Japan.
Satoh
S
S
Oyama
H
H
Takayasu
M
M
Shibuya
M
M
D000792:Angiography; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D002536:Cerebral Arteries / Q000033:anatomy & histology / Q000187:drug effects*; D002941:Circle of Willis / Q000187:drug effects*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D009569:Nitric Oxide; D012039:Regional Blood Flow / Q000187:drug effects; D013373:Substance P / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects*; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014711:Vertebral Artery; D019323:omega-N-Methylarginine
D014667:Vasopressins; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D001120:Arginine